

Supplementary Information

Hyperreflective Foci in Predicting the Treatment Outcomes of Diabetic Macular Oedema After Anti-vascular Endothelial Growth Factor Therapy

Chu-Hsuan Huang,¹ Chang-Hao Yang,^{2,3} Yi-Ting Hsieh,² Chung-May Yang,^{2,3} Tzyy-Chang Ho,² Tso-Ting Lai^{2,4*}

1 Department of Ophthalmology, Cathay General Hospital, Taipei, Taiwan

2 Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan

3 Department of Ophthalmology, College of Medicine, National Taiwan University, Taipei, Taiwan

4 Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

*Corresponding Author:

Tso-Ting Lai, MD

Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan;

Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan

University, Taipei, Taiwan

No 7, Chung-Shan S. Rd., Taipei, 100, Taiwan.

Office voice: 886-2-23123456 ext 65205

E-mail: b91401005@ntu.edu.tw

Supplementary Table S1

Predicting factors for best-corrected visual acuity improvement and central foveal thickness reduction at 1 year in patients with diabetic macular oedema under anti-vascular endothelial growth factor therapy.

	VA change at the 12 th month		CFT Change at the 12 th month	
	P-value	Coefficient	P-value	Coefficient
Age	0.395	0.002	0.096	1.41
Sex (Female =1)	0.524	0.049	0.312	16.17
HbA1c	0.189	-0.034	0.926	-0.660
Hypertension	0.001	0.209	0.878	2.49
Pseudophakia	0.698	0.027	0.710	-6.83
Previous treatment	0.031	0.136	0.761	5.32
Proliferative diabetic retinopathy	0.156	0.094	0.919	-1.83
Hard exudate	0.201	-0.074	0.014	-38.18
Drug type (Aflibercept=1)	0.241	0.070	0.030*	34.83
Baseline VA (LogMAR)	<0.001	-0.337	0.055	-50.49
Baseline CFT	0.805	0.000067	<0.001	-0.834
Baseline epiretinal membrane	0.048	0.123	0.001	54.23
Baseline intraretinal cyst	0.133	0.126	0.771	6.95
Baseline subretinal fluid	0.001	-0.209	0.001	-61.33
Baseline HRF in the inner retina	0.285	-0.018	0.033	-9.69
Baseline HRF in the outer retina	0.037	-0.007	<0.001	-4.03
VA at the 3 rd month (LogMAR)	<0.001	0.711	0.202	-29.37
CFT at the 3 rd month	0.05	0.001	<0.001	0.72
IVIs at the 3 rd month	0.567	-0.042	0.248	-25.35
IVIs at the 6 th month	0.419	0.025	0.747	-4.01
IVIs at the 12 th month	0.749	-0.005	0.410	-3.47
HRF in the inner retina at the 3 rd month	0.645	-0.009	0.493	-3.86
HRF in the outer retina at the 3 rd month	0.024	-0.01	0.009	-3.06

VA: visual acuity, CFT: central foveal thickness, IVIs: Intravitreal injections, HRF: hyperreflective foci.

*corrected with presence of epiretinal membrane at baseline: p = 0.131